Investing.com - Omeros Corporation (NASDAQ:OMER) shares are moving higher after the company announced positive long-term data on OMS721 in patients with immunoglobulin A (IgA) nephropathy.
Three of the four patients in the Phase 2 clinical trial continued to experience substantial reductions in proteinuria (protein in the urine) one year after treatment. Commenting on the results, Professor of renal medicine in the Department of Infection, Immunity & Inflammation at University of Leicester Jonathan Barratt, Ph.D., F.R.C.P. said: “The durable reduction in proteinuria that we’re seeing with OMS721 for one year after cessation of treatment is unprecedented in my experience. With this one-year follow-up, we are also seeing improvement in eGFR, which usually takes significantly longer to be evident. Two of the four patients demonstrated a slight increase, with one of the patients showing an exciting response of 50 percent improvement.”
The Phase 3 study will start later this year.
Omeros shares were up 6.4% in afternoon trade. They have gained 152% so far this year.